CAR T-cell trial for CD30-positive lymphomas that came back
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This early-phase study tests a donor-made immune cell treatment designed to attack CD30-positive lymphomas that are relapsed or refractory. If you qualify, it could help by finding a safer, effective way to control the lymphoma using engineered T-cells.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have Hodgkin lymphoma or a specific type of aggressive non-Hodgkin lymphoma, including certain T-cell lymphomas
- Your tumor has CD30 protein on it (confirmed by a certified lab test)
- You are age 12 to 75 and not pregnant or breastfeeding
- Your body can handle treatment: certain blood/liver/kidney and heart/lung checks are within limits
- You must be well enough overall (performance score above 60%) and recover from prior side effects
- You can’t have had certain recent cancer treatments, vaccines, infections, or specific steroid doses
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment using your own immune cells (T-cells) that are specially designed to attack a protein called CD30 found on Hodgkin lymphoma cells. It's given after a stem cell transplant to try to prevent the cancer from coming back in people with high-risk disease.
This trial tests a new type of immunotherapy called CAR-T cells—specially engineered immune cells designed to target and destroy Hodgkin lymphoma that has come back after initial treatment. It's designed for patients with low-risk disease who respond well to re-induction (initial salvage) therapy.
This Phase 1 trial tests a new immune therapy made from your own immune cells (CAR T cells) for relapsed or refractory Hodgkin or non-Hodgkin lymphoma that has CD30 on the tumor. It aims to see if the treatment can shrink the lymphoma and find the safest dose.
This trial tests a new type of immune cell therapy for CD30-positive lymphomas. The cells are made from donated blood and are designed to find and attack your cancer.
This trial tests a new treatment made from your own immune cells, which are modified to find and attack CD30-positive lymphoma cells. It is for people with Hodgkin or non-Hodgkin lymphoma that has come back or not responded to other treatments.
This trial tests a new type of cell therapy for people with certain types of lymphoma (Hodgkin or diffuse large B-cell) that did not respond fully to first treatment or came back within a year. The therapy uses modified natural killer (NK) cells that target a protein called CD70 found on the cancer cells.
Hear when a new Classical Hodgkin Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.